← Evidence map

ArticleTherapeutic advances in medical oncology2025

Cost-effectiveness analysis of belzutifan versus everolimus for previously treated advanced clear cell renal cell carcinoma in the United States and China.

Baolong Ding et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

3 papers cite it

2025
2026
this papercites it
Full record →Abstract, authors, funding and every citing paper · PMID 41049582